Imara Reports Second Quarter 2020 Financial Results and Business Highlights
August 14, 2020 07:00 ET
|
Imara, Inc.
Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial Reported Phase 2a interim safety and...
Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease
August 13, 2020 16:01 ET
|
Imara, Inc.
BOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Webcast Conference Call of Second Quarter 2020 Financial Results
August 07, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Cyclerion Therapeutics Completes $24 Million Private Placement
July 30, 2020 09:00 ET
|
Cyclerion Therapeutics, Inc.
- Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease - - IW-6463 translational pharmacology and olinciguat STRONG Phase...
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
July 30, 2020 07:00 ET
|
Imara, Inc.
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Added to Membership of U.S. Small-Cap Russell 2000® Index
June 29, 2020 16:01 ET
|
Imara, Inc.
BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Gazelle® Diagnostic Platform, Designed for Low Resource Settings, Integrates Miniaturized Technologies with AI to Transform Disease Screening and Diagnosis
June 17, 2020 03:01 ET
|
Hemex Health
8-minute, Low-Cost Diagnostic Test for Sickle Cell Disease (SCD) Among First Approved Tests Includes a One-Minute Malaria Test with Solutions for Other Health Priorities to Follow PORTLAND, Ore. and...
Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress
June 12, 2020 07:00 ET
|
Imara, Inc.
Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of...
Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress
May 21, 2020 07:00 ET
|
Imara, Inc.
BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports First Quarter 2020 Financial Results and Business Highlights
May 07, 2020 07:00 ET
|
Imara, Inc.
Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in sickle cell disease and...